1. FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug — Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 — Novo Nordisk's Ozempic wins FDA label boost with CV indication — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Hizentra IC plan seems flawed.

Discussion in 'CSL Behring' started by anonymous, Aug 13, 2019 at 7:06 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Isn’t it cool they designed a bonus plan that results in reps making less when we sell significantly more?
    Thanks guys. It’s fun out here.
    Anyone think they will make more than they did before with these CIDP goals? Maybe 2-3 people? Am I seeing this right?